Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918099 | 0.82 | GABRA1 (0.43) | GABRA1GABRB2POLBKDM4EMEN1 | |
| SCHEMBL2141001 | 0.82 | GABRA1 (0.44) | GABRA1GABRB2POLBKDM4ETDP1 | |
| SCHEMBL10879094 | 0.78 | IMPDH2 (0.42) | TDP1MEN1LMNATHRBBLM | |
| SCHEMBL8518278 | 0.78 | SRD5A1 (0.46) | GABRA1GABRB2POLBKDM4EMEN1 | |
| SCHEMBL10904076 | 0.76 | GABRA1 (0.39) | GABRA1GABRB2POLBKDM4EMEN1 | |
| SCHEMBL9397812 | 0.75 | GABRA1 (0.35) | GABRA1GABRB2POLBSRD5A1 | |
| SCHEMBL28717434 | 0.74 | SRC (0.35) | GABRA1GABRB2POLBKDM4ETDP1 | |
| SCHEMBL6907532 | 0.74 | GABRA1 (0.48) | GABRA1GABRB2POLBKDM4EMEN1 | |
| SCHEMBL3799650 | 0.74 | GABRA1 (0.41) | GABRA1GABRB2POLBKDM4ETDP1 | |
| SCHEMBL7194028 | 0.73 | ERN1 (0.42) | GABRA1GABRB2POLBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1264845-C | 1,2,4,5-pyromellitic anhydride preparation | NIPPON CATALYTIC CHEM IND (JP) | 2006-07-19 | — | — | CN | claimed |
| US-20060148900-A1 | Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUTOS FARMACEUTICOS LDA (PT) | 2006-07-06 | — | — | US | claimed |
| CN-1177790-C | Method for producing 2,4,5-trialkyl-benzaldehyde | 株式会社日本触媒 | 2004-12-01 | — | — | CN | claimed |
| CN-1159279-C | Method for preparing 1,2,4,5-pyromellitic anhydride | ��ʽ�����ձ���ý | 2004-07-28 | — | — | CN | claimed |
| US-6699999-B2 | Process for producing pyromellitic anhydride | NIPPON SHOKUBAI CO., LTD. (JP) | 2004-03-02 | — | — | US | claimed |
| CN-1406941-A | 1,2,4,5-pyromellitic anhydride preparation | NIPPON CATALYTIC CHEM IND (JP) | 2003-04-02 | — | — | CN | claimed |
| US-20030032816-A1 | Process for producing pyromellitic anhydride | NIPPON SHOKUBAI CO., LTD. | 2003-02-13 | — | — | US | claimed |
| CN-1349992-A | Method for preparing 1,2,4,5-pyromellitic anhydride | NIPPON CATALYTIC CHEM IND (JP) | 2002-05-22 | — | — | CN | claimed |
| CN-1345715-A | Method for producing 2,4,5-trialkyl-benzaldehyde | NIPPON CATALYTIC CHEM IND (JP) | 2002-04-24 | — | — | CN | claimed |
| CN-103657631-A | Catalyst and method for producing carboxylic acid and/or carboxylic anhydride in the presence of the catalyst | MITSUBISHI GAS CHEMICAL CO | 2014-03-26 | — | — | CN | disclosed |
| CN-101632925-B | Catalyst and process for producing carboxylic acid and/or carboxylic acid anhydride using the same | MITSUBISHI GAS CHEMICAL CO | 2014-02-26 | — | — | CN | disclosed |
| US-8173630-B2 | Multipodal tethers for high-density attachment of redox-active moieties to substrates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-08 | — | — | US | disclosed |
| CN-101632925-A | Catalyst and process for producing carboxylic acid and/or carboxylic acid anhydride using the same | MITSUBISHI GAS CHEMICAL CO | 2010-01-27 | — | — | CN | disclosed |
| CN-100443456-C | High purity 3,4-dimethyl benzaldehyde preparation method | UNIV JIANGSU POLYTECHNIC (CN) | 2008-12-17 | — | — | CN | disclosed |
| CN-1345715-A | Method for producing 2,4,5-trialkyl-benzaldehyde | NIPPON CATALYTIC CHEM IND (JP) | 2002-04-24 | — | — | CN | disclosed |
| EP-1193238-A1 | Process for producing 2,4,5-trialkylbenzaldehydes | Nippon Shokubai Co., Ltd. (JP) | 2002-04-03 | — | — | EP | disclosed |
| CN-1273230-A | Method for preparing dialkyl and trialkyl substituted benzaldehyde | MILLIKEN CO (US) | 2000-11-15 | — | — | CN | disclosed |
| US-4598157-A | Method for the manufacture of pyromellitic acid dianhydride | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | disclosed |
| EP-0064690-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED BENZALDEHYDES | BAYER AG (DE) | 1985-03-13 | — | — | EP | disclosed |
| EP-0064690-A1 | Process for the preparation of substituted benzaldehydes | BAYER AG (DE) | 1982-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148900-A1 | Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof | TNF, PTGS1, COX15 | GABRA1 3313/4885GABRB2 3704/4885POLB 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.